Responses
Clinical/translational cancer immunotherapy
Short report
Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA
Compose a Response to This Article
Other responses
No responses have been published for this article.